Skip to main content
Fig. 2 | Journal of Experimental & Clinical Cancer Research

Fig. 2

From: Development and evaluation of novel tumor-targeting paclitaxel-loaded nano-carriers for ovarian cancer treatment: in vitro and in vivo

Fig. 2

The release profiles and the pharmacokinetics features of different groups. Notes: (a) The drug release profiles of free PTX solutions, PTX-PEG-PLA-NP and PTX-PEG-PLA-FA-NP. The PTX cumulative release rate in free PTX group increased markedly over that of other two PTX-NP groups after 4 h, which indicated that the nano-carriers exhibited delayed drug release; (b) The pharmacokinetics results in different drug groups. The elimination phase (t1/2,β) of PTX-PEG-PLA-NP and PTX-PEG-PLA-FA-NP solutions (13.47 h and 15.92 h) were much longer than that of PTX solution (6.41 h, p < 0.05). The AUC was 159.81 μg/ml/h for PTX-PEG-PLA-NP and 132.72 μg/ml/h for PTX-PEG-PLA-FA-NP, which were both approximately three-fold greater than that of free PTX (52.65 μg/ml/h)

Back to article page